Andrew Booth - Dec 7, 2021 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role
Chief Financial Officer
Signature
/s/ Tryn Stimart, attorney in fact
Stock symbol
ABCL
Transactions as of
Dec 7, 2021
Transactions value $
$0
Form type
4
Date filed
12/9/2021, 04:58 PM
Previous filing
Nov 15, 2021
Next filing
Dec 10, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ABCL Common Shares 53.5K Dec 7, 2021 Direct
holding ABCL Common Shares 131K Dec 7, 2021 By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABCL Share Option (right to buy) Award $0 +406K +7.41% $0.00 5.88M Dec 7, 2021 Common Shares 406K $14.55 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on December 7, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date